Scientific Sessions 2024  /  Bridging the Gaps in the Management of Cardiac Amyloidosis - Where are we in 2024?  /  Novel Therapies in the Management of Cardiac Amyloidosis and Access to Care
Logo

American Heart Association

  145
  0

Final ID:

Novel Therapies in the Management of Cardiac Amyloidosis and Access to Care

  • Falk, Rodney  ( Brigham and Women's Hospital Heart and Vascular Center , Boston , Massachusetts , United States )
  • Kittleson, Michelle  ( Cedars Sinai , Los Angeles , California , United States )
  • Cuddy, Sarah  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
    • Author Disclosures:
    Rodney Falk: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Novo Nordisk: DSMB:Active (exists now) ; Consultant:Alnylam:Active (exists now) ; Other (please indicate in the box next to the company name):Alexion: DSMB:Active (exists now) | Michelle Kittleson: DO NOT have relevant financial relationships | Sarah Cuddy: DO have relevant financial relationships ; Advisor:Bridgebio:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Astra Zeneca:Active (exists now) ; Speaker:Pfizer:Active (exists now) ; Speaker:Novo Nordisk:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Bridging the Gaps in the Management of Cardiac Amyloidosis - Where are we in 2024?

Sunday, 11/17/2024 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Role of Artificial Intelligence in Screening and Diagnosis of Cardiac Amyloidosis in a Diverse Patient population 10 minutes

Grogan Martha, Harmon David

5 Key Lessons learned about Cardiac Amyloidosis in the last 10 years and what remains to be learned. 10 minutes

Maurer Mathew, Ambardekar Amrut

More abstracts from these authors:
The Final Battle: Advanced Heart Failure and AF - HF Top 5 Take Aways

Ambardekar Amrut, Kittleson Michelle

Do Emerging HFpEF Treatments Work? The Role of Non-disease Modifying Treatments including SGLT2i, MRAs, GLP1s, and implantable hemodynamic monitors in Cardiac Amyloidosis.

Cuddy Sarah, Griffin Jan

You have to be authorized to contact abstract author. Please, Login
Not Available